世界のワクチンアジュバント市場 – 業界動向と2030年までの予測

ワクチンアジュバント市場の分析と規模

世界のワクチンアジュバント市場は、今後数年間で大幅な成長を遂げると予想されています。感染症の蔓延の増加、ワクチン接種プログラムの拡大、アジュバント開発の進歩などの要因が市場拡大を牽引しています。さらに、新興疾患に対するワクチン開発への注目の高まりと、ワクチンの有効性と安全性の向上の必要性も、市場の成長に寄与しています。                                

データブリッジマーケットリサーチは、2022年に13億5,060万米ドルであった世界のワクチンアジュバント市場は、2030年までに29億5,057万米ドルに急増し、予測期間中に13.37％のCAGRを達成すると予測しています。これは、市場価値を示しています。感染症用ワクチンの需要が高まっているため、「感染症」がワクチンアジュバント市場の疾患タイプセグメントを支配すると予想されています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、データブリッジマーケットリサーチがまとめた市場レポートには、詳細な専門家分析、患者疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

ワクチンアジュバント市場の範囲とセグメンテーション

市場の定義

ワクチンアジュバントは、抗原に対する体の免疫反応を強化するために摂取される化合物です。ワクチンアジュバントは幅広い用途に使用されます。

世界のワクチンアジュバント市場の動向

ドライバー

• 増大する世界の疾病負担

感染症の蔓延と新たな病原体の出現は、世界中で引き続き重大な医療課題を引き起こしています。このため、効果的なワクチン、そしてワクチンアジュバントの需要が高まっています。ワクチンの有効性の向上と、より広範囲の病原体に対する防御能力の必要性が、アジュバントワクチンの開発と使用を推進しています。

• ワクチン接種プログラムの拡大

世界中の政府や医療機関は、感染症の蔓延を防ぐため、ワクチン接種プログラムを積極的に拡大しています。これには、定期予防接種、国家予防接種キャンペーン、伝染病やパンデミックに対応したワクチン接種イニシアチブが含まれます。アジュバントの需要は、免疫反応を強化し、これらのプログラムで使用されるワクチンの有効性を向上させる必要性から生じています。

• 予防医療への注目の高まり

感染症の負担を軽減するために、ワクチン接種を含む予防医療対策がますます重視されています。ワクチンの費用対効果と公衆衛生上の利点が認識されたことで、予防接種プログラムへの注目が高まっています。ワクチンアジュバントは、ワクチンの有効性を高め、望ましい免疫反応を達成する上で重要な役割を果たし、市場の成長を支えています。

• 医療施設への投資増加

Surging focus on improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor fostering the growth of the market. The rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Technological Advancements in Vaccine Manufacturing

The advancement of vaccine manufacturing technologies, such as cell culture-based and recombinant DNA technologies, has enabled the production of more complex and targeted vaccines. Adjuvants play a critical role in optimizing these advanced vaccine formulations and improving their immunogenicity. As the vaccine manufacturing landscape evolves, the demand for adjuvants that can complement and enhance these technologies is expected to increase.

• Advancements in Adjuvant Technologies

The field of adjuvant research and development is continuously advancing, leading to the discovery and development of new and improved adjuvant technologies. Novel adjuvants offer enhanced safety profiles, improved immune responses, and better compatibility with vaccine formulations. The development of innovative adjuvant platforms drives the market by enabling the creation of more effective and tailored vaccines.

Restraints

• Stringent Regulatory Requirements

Vaccine adjuvants are subject to rigorous regulatory scrutiny due to their direct involvement in the immune response and safety considerations. The regulatory approval process for adjuvant vaccines can be complex and time-consuming. Stringent regulatory requirements may pose challenges for companies developing and commercializing vaccine adjuvants, leading to delays in market entry and increased costs.

• Safety Concerns and Public Perception

Safety concerns surrounding adjuvant vaccines can impact market acceptance. Although adjuvants are generally considered safe, rare adverse events or public controversies related to vaccine safety can erode public trust and confidence in adjuvant vaccines. Communicating the safety profile and benefits of adjuvant vaccines effectively to the public is crucial for market adoption.

Challenges

• Regulatory Hurdles and Approval Processes

Vaccine adjuvants are subject to stringent regulatory requirements, and gaining regulatory approval can be a significant challenge. Adjuvants are considered an integral part of the vaccine formulation, and their safety, efficacy, and stability must be thoroughly evaluated. The regulatory process often involves extensive preclinical and clinical studies, which can be time-consuming and costly. Navigating the complex regulatory landscape and meeting the requirements pose challenges for companies developing and commercializing vaccine adjuvants.

• Cost and Affordability

Vaccine adjuvants can contribute to the overall cost of vaccine development and production. The cost-effectiveness of adjuvants, especially when combined with the cost of adjuvant vaccine production, can be a challenge. Balancing the need for improved vaccine efficacy and immune response with the cost implications is a critical consideration for both manufacturers and healthcare systems. Developing cost-effective adjuvants and optimizing manufacturing processes to reduce production costs are ongoing challenges in the market.

This vaccine adjuvants market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the vaccine adjuvants market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In April 2022, GSK and SK Bioscience submitted a biologics license application to the Korean Ministry of Food and Drug Safety (KMFDS) for their SKYCovione following positive Phase III clinical data. It is a recombinant protein-based COVID-19 vaccine candidate adjuvanted with GSK’s pandemic adjuvant
• In February 2022, Sanofi and GSK intended to submit data from their booster and Phase 3 efficacy trials as the basis for regulatory applications for a COVID-19 vaccine.

Global Vaccine Adjuvants Market Scope

The vaccine adjuvants market is segmented on the basis of product type, route of administration, disease type, application, application category, and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Particulate adjuvants
• Adjuvant emulsions
• Pathogen components
• Combination adjuvants
• Liposome adjuvants
• Carbohydrate adjuvants
• Alum
• Others

Route of Administration

• Intramuscular route
• Subcutaneous route
• Intranasal route
• Oral route
• Intradermal route
• Others

Disease Type

• Infectious diseases
• Cancer
• Others

Application

• Research application
• Commercial application

Application Category

• Human vaccine adjuvants
• Veterinary vaccine adjuvants

End-User

• Pediatric
• Adults
• Others

Vaccine Adjuvants Market Regional Analysis/Insights

The vaccine adjuvants market is analysed and market size insights and trends are provided by country, product type, route of administration, disease type, application, application category, and end-user as referenced above.

The countries covered in the vaccine adjuvants market report are U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of the Middle East and Africa.

North America is expected to dominate the vaccine adjuvants market owing to the well-established veterinary healthcare infrastructure.   

Asia-Pacific is projected to score the highest growth rate and exhibit the highest CAGR for the forecast period. This is because of the rising expenditure to develop veterinary healthcare infrastructure and the increased focus of the government on immunization programs.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The vaccine adjuvants market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for the vaccine adjuvants market, impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the vaccine adjuvants market. The data is available for the historic period 2015-2020.

Competitive Landscape and Vaccine Adjuvants Market Share Analysis

The vaccine adjuvants market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the vaccine adjuvants market.

Some of the major players operating in the vaccine adjuvants market are:

• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Astrazeneca (U.K.)
• Abbott (U.S.)
• 3M (U.S.)
• Adjuvatis (France)
• Merck KGaA (Germany)
• Croda International Plc (U.K.)
• Novavax, Inc. (U.S.)
• InvivoGen (France)
• CSL Limited (Australia)
• SPIファーマ（米国）
• フィブロアニマルヘルスコーポレーション（米国）
• SEPPIC（フランス）
• アジェナス株式会社（米国）
• OZバイオサイエンス（フランス）
• キネタ社（米国）
• ヴァキシン（オーストラリア）
• アステラス製薬株式会社（日本）
• CureVac AG（ドイツ）
• バイエルン・ノルディック（デンマーク）

SKU-14379